Literature DB >> 8502376

Impaired cognitive shifting in parkinsonian patients on anticholinergic therapy.

K P Van Spaendonck1, H J Berger, M W Horstink, E L Buytenhuijs, A R Cools.   

Abstract

In this study we established that cognitive shifting, an ability that is known to be affected in PD, is more impaired in PD patients, treated with anticholinergics, than in de novo patients. Eleven PD patients on anticholinergic monotherapy were compared with 30 de novo patients. The groups did not differ with respect to age, duration and severity of PD, and depression, nor with respect to general intelligence or attention. We assessed cognitive shifting with three different card-sorting tests. The patients on anticholinergics showed a poorer performance on all card-sorting tests than the de novo patients did. The patients on anticholinergics needed significantly more trials in two card-sorting tests and discovered significantly less categories in total. There was also a significant difference in memory performance, but memory performance did not correlate with any score on the card-sorting tests. This indicates that the performance on card-sorting tests and the memory performance were independent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8502376     DOI: 10.1016/0028-3932(93)90164-u

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  3 in total

Review 1.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

2.  Smoking, processing speed and attention in a choice reaction time task.

Authors:  T Bates; G Mangan; C Stough; P Corballis
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

Review 3.  Dopamine and Acetylcholine, a Circuit Point of View in Parkinson's Disease.

Authors:  Giorgio Rizzi; Kelly R Tan
Journal:  Front Neural Circuits       Date:  2017-12-22       Impact factor: 3.492

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.